Despite first director decisions, Arthrex reviews remain clouded in uncertainty

The jury is still out on whether the interim USPTO measures represent a meaningful process or a rubber stamping exercise, while some worry the agency’s acting head Drew Hirshfeld lacks standing to issue them


Get unlimited access to all IAM content